Succimer

also known as DMSA · 2,3-meso-dimercaptosuccinic acid · dimercaptosuccinic acid

Developed for: acute myeloid leukemia · lead poisoning · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · myelodysplastic syndrome · myelodysplastic/myeloproliferative neoplasm · Wilson disease · autism
Investigated by: M.D. Anderson Cancer Center · Congressionally Directed Medical Research Programs · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · National Institute of Environmental Health Sciences (NIEHS) · Nationwide Children's Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	CHEMET	—	1991-01-30	fda.gov ↗

Trials 5

today

US approved 1991

NCT06811233 · Ph 2 NCT03957720 · Ph 0 NCT03630991 · Ph 1 NCT00004838 · not/applicable NCT00342849 · Ph 3

19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT03957720	Mar 2019 → Dec 2024	Wilson disease	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 11 trial
Phase 1	NCT03630991	Oct 2018 → Apr 2027 expected	acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 21 trial
Phase 2	NCT06811233	May 2025 → Aug 2029 expected	acute myeloid leukemia	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 31 trial
Phase 3	NCT00342849	Jul 1994 → Aug 2007	lead poisoning	National Institute of Environmental Health Sciences (NIEHS)	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT00004838	Sep 1997 → Jul 1998	lead poisoning	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Comparator or background therapy1 trial
Phase 1/2	NCT00811083 Comparator	May 2005 → Apr 2007	autism	Southwest College of Naturopathic Medicine	Completed	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

Field	Value	Cited text
Known as	Succimer	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00342849 ↗ 2 NCT00004838 ↗ NCT03630991 ↗
Known as	2,3-meso-dimercaptosuccinic acid	“Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead.” NCT00342849 ↗
Known as	dimercaptosuccinic acid	“receiving succimer (dimercaptosuccinic acid; DMSA) plus standard treatment” NCT00004838 ↗
Known as	DMSA	“receiving succimer (dimercaptosuccinic acid; DMSA) plus standard treatment” NCT00004838 ↗ 3 NCT00811083 ↗ NCT06811233 ↗ NCT03957720 ↗
Modality	Small molecule	“an orally active dithiol compound” NCT00342849 ↗
Route	Oral	“Succimer is administered orally” NCT00004838 ↗